Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Analysis (n=5047) found no significant differences in cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or individual components, by treatment group, but liraglutide group had lower risk of MACE-5, MACE-6 and heart failure hospitalisation vs other groups combined.
Source:
Circulation
SPS commentary:
The prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalisation or revascularisation), MACE-5 (MACE-4+coronary revascularisation), MACE-6 (MACE-5+hospitalisation for heart failure), and the individual components.